

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺 诚 健 华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9969)

2024 QUARTERLY REPORT FOR THE FIRST QUARTER

This announcement is made by InnoCare Pharma Limited (the “**Company**”) pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “InnoCare Pharma Limited 2024 First Quarterly Report” (the “**2024 First Quarterly Report**”) published by the Company on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2024 First Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee of the Company, but have not been reviewed by the independent auditors of the Company.

The unaudited financial data in the 2024 First Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People’s Republic of China instead of the International Financial Reporting Standards, and are prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 13 May 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jisong Cui as Chairperson and executive Director; Dr. Renbin Zhao as executive Director; Dr. Yigong Shi, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Ms. Lan Hu, Dr. Kaixian Chen and Dr. Dandan Dong as independent non-executive Directors.

2024 FIRST QUARTERLY REPORT

Stock Code: 688428

Ticker Symbol: InnoCare

InnoCare Pharma Limited **2024 FIRST QUARTERLY REPORT**

The board of directors and all directors of the Company affirm that this announcement contains no false records or misleading statements or material omissions and that they are responsible for the truthfulness, accuracy, and completeness of its contents in accordance with the laws.

IMPORTANT NOTICE

The board of directors, directors and senior management of the Company undertake that the contents of the quarterly report are true, accurate, complete and without any false records, misleading statements or material omissions and are severally and jointly liable therefor.

The person in charge of the Company, person in charge of accounting function and person in charge of the Accounting Department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial information contained in the quarterly report.

Whether the first quarterly financial statements have been audited

☐ Yes ☒ No

MANAGEMENT PERFORMANCE REVIEW

The management of InnoCare Pharma Limited (“InnoCare” or the “Company”) commented, “The Company is a high-tech innovative biopharmaceutical enterprise driven by outstanding independent research and development capabilities, possessing comprehensive research and development, manufacturing and commercialization abilities. It focuses on areas with significant unmet clinical needs such as oncology and autoimmune diseases, developing drugs with breakthrough potential that are either first-in-class or best-in-class on a global scale.

Sales revenue of the Company’s core product, Orelabrutinib (宜諾凱®), has continued to increase. From January to March 2024, it recorded sales revenue of RMB164 million, representing a year-over-year increase of 9%. Ushering in 2024, with the new National Reimbursement Drug List implemented, Orelabrutinib’s three indications: adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy (r/r CLL/SLL), adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy (r/r MCL), and adult patients with marginal zone lymphoma (MZL) who have received at least one prior therapy (r/r MZL), are all covered by medical insurance. Orelabrutinib is the first and

2024 FIRST QUARTERLY REPORT

only BTK inhibitor approved in China for the MZL indication and is recommended as a Class I option of second-line treatment for marginal zone lymphoma (MZL) in the Chinese Society of Clinical Oncology (“CSCO”) Diagnosis and Treatment Guidelines for Malignant Lymphoma for 2024. In addition, the Company has further strengthened its core commercial management team, continuously enhanced its commercialization capabilities and optimized its execution strategies, laying a solid foundation for accelerated growth. From January to March 2024, the Company recorded operating revenue of RMB166 million. Moreover, the Company has continued to improve its gross profit margin, which amounted to 85.4% from January to March 2024, representing an increase of 8.1 percentage points from 77.3% of the same period last year.

As of 31 March 2024, the Company held approximately RMB8.2 billion in cash and bank balances. With sufficient cash reserves, the Company will continue to carry out various projects in an effort to provide more and better treatment options for patients in China and around the world.”

I. KEY FINANCIAL INFORMATION

(I) Key accounting data and financial indicators

Unit: RMB Currency: Renminbi

Items	The reporting period	Increase/decrease during the reporting period compared with the same period of the previous year (%)
Operating revenue	165,824,020.34	-12.44
Among which: revenue from sales of drugs	164,803,923.62	8.87
Net profit attributable to shareholders of the listed company	-142,403,395.72	N/A
Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses	-133,949,358.24	N/A
Net cash flows generated from operating activities	-84,043,543.78	N/A
Basic earnings per share (RMB/share)	-0.08	N/A
Diluted earnings per share (RMB/share)	-0.08	N/A
Weighted average return on equity (%)	-2.01	N/A
Total R&D expenditure	177,728,720.87	26.09
R&D expenditure as a percentage of operating	107.18	Increase of 32.75 percentage points

2024 FIRST QUARTERLY REPORT

revenue (%)			
	As at the end of the reporting period	As at the end of the previous year	Increase/decrease as at the end of the reporting period compared with the end of the previous year (%)
Total assets	9,766,283,263.59	9,919,995,852.46	-1.55
Owners' equity attributable to shareholders of the listed company	7,024,469,235.10	7,147,848,684.92	-1.73

(II) Non-recurring profits and losses items and amounts

✓Applicable ☐Not applicable

Unit: RMB Currency: Renminbi

Non-recurring profits and losses items	Amount for the reporting period	Description
Government grants included in current profits and losses (excluding those closely related to the Company's normal course of business operations, in compliance with national policies and regulations, and have a continuous impact on the Company's profit or loss according to established standards)	6,912,835.57	
Other non-operating income and expenses other than the above items	31,000.10	
Other gains and losses classified to non-recurring profits or losses	-16,476,486.81	Note
Less: Effect on income tax	-	
Effect on minority interests (after tax)	-1,078,613.66	
Total	-8,454,037.48	

Note: Other gains and losses classified to non-recurring profits or loss are losses on fair value changes of convertible loan issued by the Group. It is recognized as other gains or loss classified to non-recurring profits or loss due to its special nature and contingency which will affect the normal judgment of the users of the financial statements on the operation performance and profitability of the Company.

Reasons should be provided for identifying items not listed in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses” as non-recurring profit or loss items with significant amounts, as well as for defining the non-recurring profit or loss items set out in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses” as recurring profit or loss items.

2024 FIRST QUARTERLY REPORT

☐Applicable ☒Not applicable

(III) Changes in key accounting data and financial indicators and the reasons therefor

☒Applicable ☐Not applicable

Item	Percentage change (%)	Main reason
Net profit attributable to shareholders of the listed company	N/A	The year-on-year decrease was mainly due to:
Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses	N/A	<ol style="list-style-type: none"> 1. turnaround of unrealized foreign exchange gains of the previous year to losses this year as a result of foreign exchange fluctuations; 2. a continuous increase in R&D investments; 3. a decrease in R&D service income compared with the same period last year; 4. an increase in the fair value loss of convertible loan compared with the same period last year
Net cash flows generated from operating activities	N/A	Net cash outflows for the year decreased compared with the same period last year. The decrease was mainly due to the increase in cash inflows from operating activities resulted from the increased recovery of drug revenue, which was partially offset by an increase in cash outflows from operating activities due to the expansion of operational scale
Basic earnings per share	N/A	This was primarily due to the increase in losses attributable to shareholders of the listed company
Diluted earnings per share	N/A	
R&D expenditure as a percentage of operating revenue	Increase of 32.75 percentage points	This was mainly due to the continued increase in R&D expenditures of the Company

2024 FIRST QUARTERLY REPORT

II. SHAREHOLDER INFORMATION

1. As of the end of the reporting period, the total number of issued shares of the Company was 1,762,582,452 shares, of which 1,497,934,235 shares were issued in Hong Kong, representing approximately 84.99% of the total issued shares of the Company. The number of RMB shares issued on the SSE STAR Market was 264,648,217 shares, representing approximately 15.01% of the total issued shares of the Company.

2. The Hong Kong register of members of the Company consists of HKSCC NOMINEES LIMITED (HKSCC Nominees Limited) and other registered shareholders, of which HKSCC NOMINEES LIMITED held approximately 99.999% of the Company's Hong Kong shares on behalf of non-registered shareholders, and approximately 0.001% of the Company's Hong Kong shares were held by other registered shareholders.

3. Shares held by HKSCC NOMINEES LIMITED are held on behalf of various customers. According to the disclosure information in declaration submitted by shareholders on the Hong Kong Stock Exchange, the Company displayed in the table below the shares held by HKSCC NOMINEES LIMITED after excluding the shares held by HHLR Fund, L.P. and its persons acting in concert, King Bridge Investments Limited and its persons acting in concert, Sunny View Holdings Limited and the family of Renbin Zhao, Sunland BioMed Ltd and the family of Jisong Cui and Vivo Capital Fund VIII, L.P. and its persons acting in concert, respectively.

4. The shareholdings of the top ten shareholders are listed based on the disclosure information in declaration submitted by the relevant shareholders to the Hong Kong Stock Exchange and the A share register provided by CSDC. The nature of A shareholders is reported in accordance with the categories of holders in the A share register of CSDC.

(I) Total number of ordinary shareholders and the number of preferred shareholders whose voting rights have been restored, and shareholdings of the top ten shareholders

Unit: share

Total number of ordinary shareholders as at the end of the reporting period	17,655	Total number of preferred shareholders whose voting rights have been restored as at the end of the reporting period (if any)	0
---	--------	--	---

2024 FIRST QUARTERLY REPORT

Shareholdings of the top ten shareholders (excluding lending shares for refinancing)							
Name of shareholder	Nature of shareholder	Number of shares held	Percentage of shareholding (%)	Number of restricted shares held	Number of restricted shares (including lending shares for refinancing)	Pledged, marked or frozen	
						Status of shares	Number of shares
HKSCC NOMINEES LIMITED	Unknown	730,634,157	41.4396	-	-	Unknown	-
HHLR Fund, L.P. and its persons acting in concert	Overseas legal person	208,671,222	11.8389	-	-	Unknown	-
King Bridge Investments Limited and its persons acting in concert	Overseas legal person	158,988,012	9.0202	-	-	Unknown	-
Sunny View Holdings Limited and the family of Renbin Zhao	Overseas legal person	144,617,893	8.2049	-	-	Nil	0
	Overseas natural person						
Vivo Capital Fund VIII, L.P. and its persons acting in concert	Overseas legal person	129,136,118	7.3265	-	-	Unknown	-
Sunland BioMed Ltd and the family of Jisong Cui	Overseas legal person	125,871,782	7.1413	-	-	Nil	0
	Overseas natural person						
Bank of Communications Co., Ltd. — Wanjia Sector Selection Mixed Securities Investment Fund (LOF)	Others	20,000,000	1.1347	-	-	Nil	0
Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Securities Investment Fund	Others	19,150,594	1.0865	-	-	Nil	0
GZHT Technology Holdings	State-owned legal person	8,975,521	0.5092	-	-	Nil	0
China Bohai Bank Co., Ltd. — China Securities Healthcare Reform Flexible Allocation Hybrid Securities Investment Fund	Others	8,900,000	0.5049	-	-	Nil	0

2024 FIRST QUARTERLY REPORT

Shareholdings of the top ten unrestricted shareholders			
Name of shareholder	Number of unrestricted outstanding shares held	Type and number of shares	
		Type	Number
HKSCC NOMINEES LIMITED	730,634,157	Others	730,634,157
HHLR Fund, L.P. and its persons acting in concert	208,671,222	Others	208,671,222
King Bridge Investments Limited and its persons acting in concert	158,988,012	Others	158,988,012
Sunny View Holdings Limited and the family of Renbin Zhao	144,617,893	Others	144,617,893
Vivo Capital Fund VIII, L.P. and its persons acting in concert	129,136,118	Others	129,136,118
Sunland BioMed Ltd and the family of Jisong Cui	125,871,782	Others	125,871,782
Bank of Communications Co., Ltd. – Wanjia Sector Selection Mixed Securities Investment Fund (LOF)	20,000,000	RMB-denominated ordinary shares	20,000,000
Agricultural Bank of China Limited – Penghua Pharmaceutical Technology Equity Securities Investment Fund	19,150,594	RMB-denominated ordinary shares	19,150,594
GZHT Technology Holdings	8,975,521	RMB-denominated ordinary shares	8,975,521
China Bohai Bank Co., Ltd. – China Securities Healthcare Reform Flexible Allocation Hybrid Securities Investment Fund	8,900,000	RMB-denominated ordinary shares	8,900,000
Description of the connected relationships among, or concerted actions taken by the above shareholders	The Company is not aware of whether the above other shareholders have other related relationships or concerted action relationships		
Description of the top ten shareholders and the top ten unrestricted shareholders involved in margin financing and securities lending and refinancing businesses (if any)	Nil		

Involvement of shareholders with shareholdings of more than 5%, top ten shareholders and top ten unrestricted shareholders in lending shares for refinancing businesses

2024 FIRST QUARTERLY REPORT

☐ Applicable ☒ Not applicable

Changes of top ten shareholders and top ten unrestricted shareholders as compared with the previous period due to lending/returning shares for refinancing

☐ Applicable ☒ Not applicable

2024 FIRST QUARTERLY REPORT

III. OTHER REMINDERS

Other important information about the operation of the Company during the reporting period to which investors should pay attention

☐ Applicable ☒ Not applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Types of audit opinions

☐ Applicable ☒ Not applicable

(II) Financial statements

Consolidated balance sheet

31 March 2024

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	March 31, 2024	December 31, 2023
Current assets:		
Cash and bank balances	8,201,839,334.55	8,287,136,644.81
Accounts receivable	232,958,854.23	276,377,549.08
Receivables financing	716,852.45	31,260,680.06
Prepayments	51,471,038.54	39,043,785.79
Other receivables	1,084,828.70	2,020,426.63
Including: Interests receivable	-	-
Dividends receivable	-	-
Inventories	118,157,773.43	119,094,840.89
Including: Data resources	-	-
Other current assets	14,484,933.57	10,390,135.51
Total current assets	8,620,713,615.47	8,765,324,062.77
Non-current assets:		
Long-term equity investments	4,320,662.46	5,660,187.95
Fixed assets	566,350,313.34	563,916,250.69
Construction in progress	196,069,022.25	166,908,613.33
Right-of-use assets	61,016,968.86	67,675,076.97
Intangible assets	263,496,384.80	266,034,974.53
Including: Data resources	-	-
Goodwill	3,124,706.56	3,124,706.56
Long-term prepaid expenses	31,389,685.97	33,296,596.24

2024 FIRST QUARTERLY REPORT

Other non-current assets	19,801,903.88	48,055,383.42
Total non-current assets	1,145,569,648.12	1,154,671,789.69
Total assets	9,766,283,263.59	9,919,995,852.46
Current liabilities:		
Accounts payable	118,709,174.06	134,904,878.31
Payroll payable	32,688,270.79	52,998,908.88
Taxes payable	27,323,583.61	15,252,770.76
Other payables	102,153,263.65	123,130,143.37
Including: Interests payable	-	-
Dividends payable	-	-
Non-current liabilities due within one year	30,530,432.02	28,233,387.44
Other current liabilities	1,743,943,652.35	1,727,467,165.53
Total current liabilities	2,055,348,376.48	2,081,987,254.29
Non-current liabilities:		
Long-term borrowings	33,100,000.00	26,300,000.00
Lease liabilities	35,664,330.64	43,646,576.13
Long-term payables	310,198,765.79	305,576,610.80
Deferred income	277,902,566.70	281,779,757.46
Total non-current liabilities	656,865,663.13	657,302,944.39
Total liabilities	2,712,214,039.61	2,739,290,198.68
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	23,318.12	23,315.98
Capital reserve	12,166,071,939.05	12,150,114,225.86
Less: Treasury shares	7,385,869.38	-
Other comprehensive income	87,684,017.73	77,231,919.20
Retained earnings	-5,221,924,170.42	-5,079,520,776.12
Total equity attributable to owners (or shareholders) of the parent company	7,024,469,235.10	7,147,848,684.92
Minority interests	29,599,988.88	32,856,968.86
Total owners' equity (or shareholders' equity)	7,054,069,223.98	7,180,705,653.78
Total liabilities and owners' equity (or shareholders' equity)	9,766,283,263.59	9,919,995,852.46

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu Person in charge of the Accounting Department: Yue Tan

2024 FIRST QUARTERLY REPORT

Consolidated Statement of Income

January-March 2024

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	First Quarter in 2024	First Quarter in 2023
I. Total operating revenue	165,824,020.34	189,387,628.40
Including: Operating revenue	165,824,020.34	189,387,628.40
II. Total operating costs	303,015,436.11	207,586,324.78
Including: Operating costs	24,290,417.68	42,897,028.90
Taxes and surcharges	3,036,877.51	2,273,281.01
Selling expenses	89,533,244.90	85,962,493.69
Administrative expenses	42,408,649.62	36,912,035.95
R&D expenses	177,728,720.87	140,950,687.03
Finance costs	-33,982,474.47	-101,409,201.80
Including: Interest expenses	5,177,359.39	10,360,573.20
Interest income	47,128,560.55	46,138,411.62
Exchange losses/(gains)	7,889,726.23	-65,728,471.01
Add: Other income	9,316,072.39	11,137,224.44
Investment income (loss denoted by “-”)	-1,339,525.49	-709,134.68
Including: Share of profit of associates and joint ventures	-1,339,525.49	-709,134.68
Gain from changes in fair value (loss denoted by “-”)	-16,476,486.81	-6,459,371.68
III. Operating profit (loss denoted by “-”)	-145,691,355.68	-14,229,978.30
Add: Non-operating income	31,000.10	612.90
Less: Non-operating expenses	-	-
IV. Total profit (total loss denoted by “-”)	-145,660,355.58	-14,229,365.40
Less: Income tax expenses	20.10	-
V. Net profit (net loss denoted by “-”)	-145,660,375.68	-14,229,365.40
(I) By continuity of operations		
1. Net profit from continuing operations (net loss denoted by “-”)	-145,660,375.68	-14,229,365.40
2. Net profit from	-	-

2024 FIRST QUARTERLY REPORT

discontinued operations (net loss denoted by “-”)		
(II)By attribution of ownership		
1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”)	-142,403,395.72	-12,406,466.71
2. Profit or loss attributable to minority shareholders (net loss denoted by “-”)	-3,256,979.96	-1,822,898.69
VI. Other comprehensive income, net of tax	10,452,098.53	-86,273,096.48
(I) Other comprehensive income attributable to owners of the parent company, net of tax	10,452,098.53	-86,273,096.48
1. Other comprehensive income not to be reclassified to profit or loss	10,452,098.53	-86,273,096.48
(1) Translation differences of the financial statements in foreign currency	10,452,098.53	-86,273,096.48
2. Other comprehensive income to be reclassified to profit or loss	-	-
(II) Other comprehensive income attributable to minority shareholders, net of tax	-	-
VII. Total comprehensive income	-135,208,277.15	-100,502,461.88
(I) Total comprehensive income attributable to owners of the parent company	-131,951,297.19	-98,679,563.19
(II) Total comprehensive income attributable to minority shareholders	-3,256,979.96	-1,822,898.69
VIII. Earnings per share:		
(I) Basic earnings per share (RMB/share)	-0.08	-0.01
(II) Diluted earnings per share (RMB/share)	-0.08	-0.01

For business combinations under the same control in the current period, the net profit achieved by the parties consolidated prior to the consolidation was RMB0.00; the net profit achieved by the parties consolidated in the previous period was RMB0.00.

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu Person in charge of the Accounting Department: Yue Tan

2024 FIRST QUARTERLY REPORT

Consolidated Statement of Cash Flows

January-March 2024

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	First Quarter in 2024	First Quarter in 2023
I. Cash flows generated from operating activities:		
Cash receipts from sales of goods and provision of services	268,172,063.57	183,364,208.30
Cash received from other operating activities	20,650,437.77	4,175,885.99
Sub-total of cash inflows from operating activities	288,822,501.34	187,540,094.29
Cash paid for goods and services	180,566,928.06	147,213,484.77
Cash paid to and on behalf of employees	157,277,358.24	147,592,193.50
Cash paid for taxes and levies	10,258,771.66	24,418,927.41
Cash paid for other operating activities	24,762,987.16	23,117,898.39
Sub-total of cash outflows from operating activities	372,866,045.12	342,342,504.07
Net cash flows generated from operating activities	-84,043,543.78	-154,802,409.78
II. Cash flows generated from investment activities:		
Cash received from the disposal of investments	1,015,590,381.62	1,022,369,085.19
Cash received from investment income	28,096,224.65	14,521,601.13
Sub-total of cash inflows from investment activities	1,043,686,606.27	1,036,890,686.32
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	26,011,755.52	43,222,921.57
Cash paid for investments	515,000,000.00	995,583,150.00
Sub-total of cash outflows from investment activities	541,011,755.52	1,038,806,071.57
Net cash flows generated from investing activities	502,674,850.75	-1,915,385.25
III. Cash flows generated from financing activities:		
Cash received from capital contributions	718,358.35	868,634.75

2024 FIRST QUARTERLY REPORT

Cash received from borrowings	6,800,000.00	-
Sub-total of cash inflows from financing activities	7,518,358.35	868,634.75
Cash paid for distribution of dividends or profits or settlement of interest	287,534.72	1,009,584.20
Cash paid for other financing activities	14,671,100.35	8,024,532.69
Sub-total of cash outflows from financing activities	14,958,635.07	9,034,116.89
Net cash flows generated from financing activities	-7,440,276.72	-8,165,482.14
IV. Effects of changes in exchange rate on cash and cash equivalents	2,726,913.06	-21,312,065.11
V. Net increase in cash and cash equivalents	413,917,943.31	-186,195,342.28
Add: Balance of cash and cash equivalents at the beginning of the period	4,202,563,804.93	4,179,983,730.99
VI. Balance of cash and cash equivalents at the end of the period	4,616,481,748.24	3,993,788,388.71

Person in charge of the Company: Jisong Cui Person in charge of accounting function: Xin Fu Person in charge of the Accounting Department: Yue Tan

Adjustment of the financial statements for the beginning of 2024 when the Company implements the new accounting standards or interpretation of standards for the first time

☐ Applicable ☒ Not applicable

The announcement is hereby made.

Board of directors of InnoCare Pharma Limited
13 May 2024